Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Inclusion Criteria

• MDS subjects with higher risk;
• Age ≥ 18 years old;
• Eastern Cooperative Oncology Group score of 0~1;
• Not suitable for or refuse to receive HSCT;
• Newly diagnosed MDS subjects;
• Adequate organ function;
• Subjects should take effective contraceptive measures
• Must sign the Informed Consent Form (ICF), and be able to follow all study procedures.

Exclusion Criteria

• Subject who has transformed from MDS to AML.
• Therapy-related MDS (t-MDS), myeloproliferative neoplasm (MPN)- transformed MDS,MDS/MPN.
• MDS subjects with lower risk.
• Subjects who have received chemotherapy.
• Prior exposure to any anti-CD47 or anti-SIRPα agents.
• Subjects participating in another interventional clinical study.